Call Us : 1.224.938.9523
The Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center and 1Florida ADRC present
  • 17th Annual Mild Cognitive Impairment Symposium
  • Special Topic Workshop
  • Alzheimer's Public Educational Forum

January 19-20, 2019 | Miami Beach, Florida, USA




Upon completion of the event, attendees should be able to:

  1. Explain the role of genetics in neurodegenerative and vascular diseases of the brain.
  2. Discuss the role of cognitive and brain reserve in the neuropsychological diagnosis of normal and abnormal aging.
  3. Describe mild behavioral impairment (MBI) and epidemiological evidence for neuropsychiatric symptoms as predictors of MCI and dementia.
  4. List important clinical trials in asymptomatic and prodromal Alzheimer’s disease.
  5. Summarize the evidence for the effect of multilingualism on brain and cognitive functioning.


APOE4, Non E4 and Epigenetics of LOAD


Brain and Cognitive Reserve


Mild Behavioral Impairment

The 2018 edition of this symposium will include three keynote addresses and several lectures, featuring national experts in the fields of neurology, psychiatry, geriatrics, neuropsychology, radiology, epidemiology, pathology and molecular biology. Each session will be followed by an extended discussion period, allowing active audience participation to promote a better understanding of the issues.  


Bilingualism, Neuropsychology, Imaging and Treatment in MCI and AD

The workshop will include a special lecture, a keynote lecture, and several podium presentations, concluding with a moderated panel discussion.  


Genetics, Cognitive Reserve, Behavior, Bilingualism and Treatment in MCI and AD

This educational forum intended for the public at large, aims to provide information about the latest research in the early detection of Alzheimer’s disease and the results from clinical drug trials, including prevention studies. The forum will allow the audience to interact with top scientists in the field in the presence of a moderator. The Forum is a free event to the public.

The 16th Annual MCI Symposium

Saturday, January 20, 2018, 8:30 am – 6 pm

Genetics, Cognitive Reserve and Behavior in MCI and Alzheimer’s Disease

Session 1


APOE4, Non E4 and Epigenetics of LOAD


The ε4 allele of apolipoprotein E (APOE) is the major genetic risk factor for late onset Alzheimer’s Disease (LOAD). Several other regions of interest in the genome have been identified which impact the age of onset of AD.

Evidence is emerging that epigenetic mechanisms may also contribute to AD pathology.

Upon completion of this session, attendees will be better able to:

  1. Describe the risk for AD associated with variations in APOE.
  2. List other genes that may play a role in LOAD.
  3. Describe how genetics and epigenetics may lead to therapy.

Session 2

Late morning and early afternoon

Cognitive and Brain Reserve


Several epidemiological studies have shown that cognitive reserve protects against cognitive decline associated with Alzheimer’s Disease. The mechanism of this protection is believed to be lifetime exposures, related to education, occupation and lifestyle. Imaging studies provide evidence that cognitive reserve protects against the burden of AD pathology.  The impact of cognitive reserve on clinical diagnosis and treatment will be presented.

Upon completion of this session, attendees should be able to:

  1. Explain the concept of cognitive reserve.
  2. Understand the role of imaging in the diagnosis and treatment of subjects with high or low cognitive reserve.
  3. Discuss the relationship between clinical progression and cognitive reserve.

Session 3

Late afternoon

Mild Behavioral Impairment


Multiple studies have shown that neuropsychiatric symptoms in MCI significantly increase the risk for progression to dementia and AD.  There is emerging evidence that a syndrome known as Mild Behavioral Impairment (MBI) may precede MCI. The recognition of MBI may lead to earlier identification of subjects at risk for clinical progression to AD, FTD and other disorders. The benefits and risks of proposed criteria for MBI will be presented.

Upon completion of this session, attendees should be able to:

  1. Summarize the evidence from epidemiological studies which show an increased risk for progression from MCI to dementia associated with neuropsychiatric symptoms.
  2. Identify five categories of behavioral symptoms in a proposed new MBI checklist (MBI-C) designed to be administered by physicians.
  3. Discuss how identification of MBI affects diagnosis and treatment recommendations.

Special Lecture

Sunday, January 21, 2018, 8:35 am-9:05 am

Treatment of Alzheimer’s Disease: Where We Are and Prospects for the Future


This lecture will provide information about the latest results from treatment trials in the field of Alzheimer’s disease, including on-going prevention trials. This lecture will also review non-non-pharmacological and pharmacological strategies for treating Alzheimer’s disease, including non-amyloid approaches.

Upon completion of this lecture, attendees should be able to:

  1. Describe results from several treatment trials.
  2. Discuss new phramacological approaches for treating Alzheimer’s disease.
  3. List reasons for the importance of participating in clinical trials in Alzheimer’s disease prevention and treatment.


Sunday, January 21, 2018, 9:35 am – 1:30 pm

Bilingualism, Neuropsychology, Imaging and Treatment in MCI and AD


This workshop will present results from several studies addressing whether bilingualism delays cognitive decline in old age. The effects of bilingualism on the brain will explored by reviewing structural and functional MRI imaging studies.   There will be additional presentations on the effects of language of administrations in bilinguals.

Upon completion of this workshop, attendees should be able to:

  1. Describe the advantages and disadvantages for bilingual adults on different cognitive tests.
  2. Discuss result from several studies suporting and refuting a beneficial effect of bilingualism on cognitive decline in old age.
  3. List the effects of bilingualism on brain function.

Public Education Forum

Sunday, January 21 2018, 1:30 pm – 5:00 pm

Genetics, Cognitive Reserve, Behavior, Bilingualism and Treatment in MCI and AD


This event is intended for the public at large, including individuals at-risk for Alzheimer’s disease, their family members, as well as professionals from various fields who may be interested in an up-to-date review of some aspects of Alzheimer’s research. The forum will allow the audience to interact with top scientists in the field in the presence of a moderator.

This educational segment aims to provide information about the latest research in the field of Alzheimer’s disease, including advances in the treatment of AD, the genetics of cognitive decline, evidence for the effect of bilingualism and lifestyle on delaying or preventing cognitive decline, and the importance of behavioral changes in aging.

Upon completion of the Forum, attendees should be able to:

  1. Describe the results from recent studies aimed at delaying Alzheimer’s disease in at-risk people.
  2. Discuss the role of genetics in Alzheimer’s disease.
  3. Explain why lifestyle has an effect on memory and cognitive decline in the elderly.
  4. List behavioral changes in aging that may be a precursor to cognitive decline.


Projections are that nearly 14 million people in the United States and 120 million people worldwide will have dementia caused by Alzheimer’s Disease (AD) and other conditions by the year 2050, a phenomenon driven by increased longevetity. All forms of dementia have a major impact on the quality of life and productivity of affected individuals, their caregivers and the community in general. Individuals with dementia suffer from cognitive and functional impairment, social isolation, problematic behaviors and overall deterioration. Many people with AD require long-term care. In addition, their caregivers are often affected physically, psychologically and financially by the burden of providing care.


Due to improvements in clinical assessment, brain imaging and biomarker methods, major advances in identifying the earliest features of AD and other causes of dementia have been made. International workgroups, including those convened by the Alzheimer’s Association and the National Institute on Aging (NIA), have provided new criteria and guidelines to diagnose Alzheimer’s disease, Lewy Body Dementia and Frontotemporal Dementia more accurately. The criteria for diagnosing a pre-dementia condition known as Mild Cognitive Impairment (MCI) have also been refined. People with MCI are at an increased risk for progressing to AD or other dementias. In addition, neuropsychiatric symptoms, such as apathy and agitation, are associated with faster progression from MCI to dementia, so their identification is clinically useful.


The early diagnosis of dementing illnesses can lead to earlier pharmacological treatment and other interventions, such as caregiver education, legal and financial counseling. Recent studies indicate that clinicians often lack knowledge of new diagnostic guidelines, resulting in inaccurate diagnoses and delays in intervention. In practice, many clinicians are also unaware of the advantages and limitations of new methods for clinical assessment and brain imaging, and how to utilize results from cognitive tests in patients with high cognitive reserve. Practioners also need information about new research in the field, including clinical trials, to better respond to patient questions about when and why to refer them to clinical trials.



Under the direction of Ranjan Duara, MD, the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center, Miami Beach, initiated the MCI Symposium in 2003.

The purpose of the first and subsequent symposia has been to provide a forum where new information is provided and in-depth discussions take place about the earliest stages of Alzheimer’s disease and other conditions that result in cognitive impairment in the elderly.   The symposia have featured national and international experts in the fields of neurology, neuropsychology, psychiatry, geriatrics, epidemiology, genetics, imaging and neuropathology. Other topics of discussion have included the biology, early detection, prevention and treatment of conditions that result in cognitive impairment in the elderly.

Each symposium has had a central theme presented in the format of three or four half-day minisymposia (each with its own subtheme) over a two-day period.   Starting with the 10th Annual MCI Symposium in 2012, the second day of the Symposium has been devoted to a Workshop in which practical issues related to diagnosis or treatment of conditions leading to MCI and dementia were discussed.

In 2013, the MCI Symposium included the First Alzheimer’s Public Educational Forum for patients, at-risk family members and caregivers. This segment originated in response to the need for increased information from the general public about risk factors, early detection, prevention and treatment of Alzheimer’s disease and related conditions



Dr. Ranjan Duara is the Medical Director and Dennis C. Cole Family Chair in Alzheimer’s Disease Research at the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center in Miami Beach. He is a Professor of Neurology at the Herbert Wertheim College of Medicine (Department of Neurology) at Florida International University and Courtesy Professor of Neurology, University of Florida College of Medicine. He completed internal medicine and neurology residencies in India, the United Kingdom and at Thomas Jefferson University Hospital in Philadelphia, and did a fellowship in neuroscience and neuroimaging at NIH.

Dr. Duara’s research has focused primarily on early diagnosis of Alzheimer’s disease and other dementias, neuroimaging, genetic epidemiology and the methodology for staging the transition from normal cognitive aging to dementia. He has contributed to over 200 articles in peer-review scientific journals as well many book chapters.

He is the Principal Investigator for the State of Florida Alzheimer’s Disease Initiative Brain Bank and Associate Director of the 1FLORIDA Alzheimer’s Disease Research Center. He has also been an investigator in numerous clinical trials of novel agents for the treatment of Alzheimer’s Disease.


MSMC Aerial high res 2008 SmallerThe Wien Center for Alzheimer’s Disease and Memory Disorders, since its inception in 1986, has provided clinical care in the form of diagnosis, comprehensive neurological, psychiatric, social service and outreach services to patients and their caregivers in South Florida, the Caribbean and Central and Central America.

The center has been very actively engaged in clinical, neuroimaging, neuropsychological, epidemiological and genetic research, as well as in clinical trials, including the Alzheimer’s Disease Neuroimaging Initiative and many studies sponsored by the Alzheimer’s Disease Cooperative Studies group as well as pharmaceutical and other healthcare companies. The center is also the host of the State of Florida Brain Bank, including a registry of autopsy donors for those afflicted with memory disorders and the only facility to obtain neuropathological diagnosis for such patients in all of South Florida.

The center has been a recipient of numerous grant awards, including a partnership in a National Institutes of Health Alzheimer’s Disease Research Center (ADRC) award. The center has been in the forefront of providing education about memory disorders to professionals and the community at large. It initiated a comprehensive community memory screening program in the early 1990s, which continues to serve hundreds of South Florida’s elderly residents each year.

While the Wien Center has been at the forefront of major advances in Alzheimer’s including diagnosis, treatment and research, for the last 25 years, there remains much to learn and investigate. The MCI Symposium, the Early Alzheimer’s Disease Workshop and the Public Education Forum are the vehicles for this learning process, not only for the center and for the residents of South Florida, but also for the many individuals who travel to Miami Beach to attend these events each year.

Discover more about the Wien Center at its website.